Who Optimizes SG&A Costs Better? Alnylam Pharmaceuticals, Inc. or Galapagos NV

Biotech Giants: A Decade of SG&A Cost Strategies

__timestampAlnylam Pharmaceuticals, Inc.Galapagos NV
Wednesday, January 1, 2014445260009079000
Thursday, January 1, 20156061000020309000
Friday, January 1, 20168935400016945000
Sunday, January 1, 201719936500020559000
Monday, January 1, 201838235900029641000
Tuesday, January 1, 201947900500088258000
Wednesday, January 1, 2020588420000162170000
Friday, January 1, 2021620639000167218000
Saturday, January 1, 2022770658000239528000
Sunday, January 1, 202379564600094252000
Monday, January 1, 2024975526000
Loading chart...

Data in motion

Optimizing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Alnylam Pharmaceuticals, Inc. and Galapagos NV, two prominent players in the industry, have shown contrasting strategies over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, Galapagos NV maintained a more conservative approach, with a 940% increase, indicating a focus on cost efficiency.

By 2023, Alnylam's SG&A expenses were approximately eight times higher than those of Galapagos, highlighting its commitment to scaling operations. However, Galapagos's steady growth in expenses suggests a strategic balance between cost management and business development. This comparison offers valuable insights into how biotech companies can navigate financial strategies to optimize their operational efficiency.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025